Abhishek Chatterjee

Find an error

Name: Chatterjee, Abhishek
Organization: Boston College , USA
Department:
Title: (PhD)
Co-reporter:Partha Sarathi Addy, Sarah B. Erickson, James S. Italia, and Abhishek Chatterjee
Journal of the American Chemical Society August 30, 2017 Volume 139(Issue 34) pp:11670-11670
Publication Date(Web):August 8, 2017
DOI:10.1021/jacs.7b05125
Chemoselective modification of complex biomolecules has become a cornerstone of chemical biology. Despite the exciting developments of the past two decades, the demand for new chemoselective reactions with unique abilities, and those compatible with existing chemistries for concurrent multisite-directed labeling, remains high. Here we show that 5-hydroxyindoles exhibit remarkably high reactivity toward aromatic diazonium ions and this reaction can be used to chemoselectively label proteins. We have previously genetically encoded the noncanonical amino acid 5-hydroxytryptophan in both E. coli and eukaryotes, enabling efficient site-specific incorporation of 5-hydroxyindole into virtually any protein. The 5-hydroxytryptophan residue was shown to allow rapid, chemoselective protein modification using the azo-coupling reaction, and the utility of this bioconjugation strategy was further illustrated by generating a functional antibody–fluorophore conjugate. Although the resulting azo-linkage is otherwise stable, we show that it can be efficiently cleaved upon treatment with dithionite. Our work establishes a unique chemoselective “unclickable” bioconjugation strategy to site-specifically modify proteins expressed in both bacteria and eukaryotes.
Co-reporter:Yunan Zheng;Partha Sarathi Addy;Raja Mukherjee
Chemical Science (2010-Present) 2017 vol. 8(Issue 10) pp:7211-7217
Publication Date(Web):2017/09/25
DOI:10.1039/C7SC02560B
The ability to site-specifically incorporate two distinct noncanonical amino acids (ncAAs) into the proteome of a mammalian cell with high fidelity and efficiency will have many enabling applications. It would require the use of two different engineered aminoacyl-tRNA synthetase (aaRS)/tRNA pairs, each suppressing a distinct nonsense codon, and which cross-react neither with each other, nor with their counterparts from the host cell. Three different aaRS/tRNA pairs have been developed so far to expand the genetic code of mammalian cells, which can be potentially combined in three unique ways to drive site-specific incorporation of two distinct ncAAs. To explore the suitability of using these combinations for suppressing two distinct nonsense codons with high fidelity and efficiency, here we systematically investigate: (1) how efficiently the three available aaRS/tRNA pairs suppress the three different nonsense codons, (2) preexisting cross-reactivities among these pairs that would compromise their simultaneous use, and (3) whether different nonsense-suppressor tRNAs exhibit unwanted suppression of non-cognate stop codons in mammalian cells. From these comprehensive analyses, two unique combinations of aaRS/tRNA pairs emerged as being suitable for high-fidelity dual nonsense suppression. We developed expression systems to validate the use of both combinations for the site-specific incorporation of two different ncAAs into proteins expressed in mammalian cells. Our work lays the foundation for developing powerful applications of dual-ncAA incorporation technology in mammalian cells, and highlights aspects of this nascent technology that need to be addressed to realize its full potential.
Co-reporter:Yunan Zheng, Tommy L. Lewis Jr., Peter Igo, Franck Polleux, and Abhishek Chatterjee
ACS Synthetic Biology 2017 Volume 6(Issue 1) pp:
Publication Date(Web):August 2, 2016
DOI:10.1021/acssynbio.6b00092
Unnatural amino acid (UAA) mutagenesis of recombinant proteins in live mammalian cells requires coexpression of the mutant target, as well as an engineered tRNA/aminoacyl-tRNA synthetase pair. The ability to readily determine the optimal relative expression levels of these three genetic components for efficient expression of the UAA-modified target is highly desirable, but remains challenging to accomplish. Here we report a facile strategy to achieve this by taking advantage of the efficient gene-delivery by a baculovirus vector, which enables systematic variation of the expression level of each genetic component in a population-wide manner. Insights gained from this study led to the design of an optimal expression system, which can be delivered into mammalian cells by a single baculovirus vector to provide significantly improved UAA incorporation efficiency at a low virus load. Furthermore, this optimized baculovirus vector was shown to enable efficient UAA mutagenesis of proteins expressed in mouse brain tissue.Keywords: mammalian genetic code expansion; unnatural amino acid incorporation; viral vector;
Co-reporter:Yunan Zheng, Marc J. Lajoie, James S. Italia, Melissa A. Chin, George M. Church and Abhishek Chatterjee  
Molecular BioSystems 2016 vol. 12(Issue 6) pp:1746-1749
Publication Date(Web):30 Mar 2016
DOI:10.1039/C6MB00070C
Site-specific incorporation of noncanonical amino acids (ncAAs) into proteins expressed in E. coli using UAG-suppression competes with termination mediated by release factor 1 (RF1). Recently, unconditional deletion of RF1 was achieved in a genomically recoded E. coli (C321), devoid of all endogenous UAG stop codons. Here we evaluate the efficiency of ncAA incorporation in this strain using optimized suppression vectors. Even though the absence of RF1 does not benefit the suppression efficiency of a single UAG codon, multi-site incorporation of a series of chemically distinct ncAAs was significantly improved.
Co-reporter:Rachel E. Kelemen;Dr. Raja Mukherjee;Xiaofu Cao;Sarah B. Erickson;Yunan Zheng ; Abhishek Chatterjee
Angewandte Chemie International Edition 2016 Volume 55( Issue 36) pp:10645-10649
Publication Date(Web):
DOI:10.1002/anie.201604067

Abstract

The ability to target the adeno-associated virus (AAV) to specific types of cells, by altering the cell-surface receptor it binds, is desirable to generate safe and efficient therapeutic vectors. Chemical attachment of receptor-targeting agents onto the AAV capsid holds potential to alter its tropism, but is limited by the lack of site specificity of available conjugation strategies. The development of an AAV production platform is reported that enables incorporation of unnatural amino acids (UAAs) into specific sites on the virus capsid. Incorporation of an azido-UAA enabled site-specific attachment of a cyclic-RGD peptide onto the capsid, retargeting the virus to the αvβ3 integrin receptors, which are overexpressed in tumor vasculature. Retargeting ability was site-dependent, underscoring the importance of achieving site-selective capsid modification. This work provides a general chemical approach to introduce various receptor binding agents onto the AAV capsid with site selectivity to generate optimized vectors with engineered infectivity.

Co-reporter:Rachel E. Kelemen;Dr. Raja Mukherjee;Xiaofu Cao;Sarah B. Erickson;Yunan Zheng ; Abhishek Chatterjee
Angewandte Chemie 2016 Volume 128( Issue 36) pp:10803-10807
Publication Date(Web):
DOI:10.1002/ange.201604067

Abstract

The ability to target the adeno-associated virus (AAV) to specific types of cells, by altering the cell-surface receptor it binds, is desirable to generate safe and efficient therapeutic vectors. Chemical attachment of receptor-targeting agents onto the AAV capsid holds potential to alter its tropism, but is limited by the lack of site specificity of available conjugation strategies. The development of an AAV production platform is reported that enables incorporation of unnatural amino acids (UAAs) into specific sites on the virus capsid. Incorporation of an azido-UAA enabled site-specific attachment of a cyclic-RGD peptide onto the capsid, retargeting the virus to the αvβ3 integrin receptors, which are overexpressed in tumor vasculature. Retargeting ability was site-dependent, underscoring the importance of achieving site-selective capsid modification. This work provides a general chemical approach to introduce various receptor binding agents onto the AAV capsid with site selectivity to generate optimized vectors with engineered infectivity.

Dibenzocyclooctyne-maleimide (This product is unavailable in the U.S.)
(S)-3-(4-Acetylphenyl)-2-aminopropanoic acid
4-Methoxy-L-phenylalanine
L-Phenylalanine, 4-azido-